Clavis Pharma Licenses Rights to hENT1 antibody to Ventana Medical Systems, Inc.

04-May-2010 - Norway

Clavis Pharma ASA announced that it has entered into a licence agreement with Ventana Medical Systems, Inc. providing Ventana with exclusive access to Clavis Pharma’s monoclonal antibody targeting human nucleoside transporter 1 (hENT1) and to the hybridoma cell line that produces the antibody. The hENT1 antibody will be used in the development of a companion diagnostic for Clavis Pharma’s drug candidate CP-4126, which is in Phase II clinical trials for the treatment of pancreatic cancer. The antibody has excellent specificity for hENT1 and has, to date, been used successfully in Clavis Pharma’s clinical programme with CP-4126.

The agreement reinforces the collaboration agreement announced on April 22, 2010 between Ventana and Clovis Oncology, Clavis Pharma’s partner for CP-4126, for the development of a companion diagnostic to CP-4126 (also known as CO-101) for clinical and commercial use.

Under the terms of the agreement, Ventana gains exclusive access from Clavis Pharma to the hENT1 antibody and hybridoma line around which Ventana will seek to develop an immuno-histochemistry (IHC) assay for use in Clovis Oncology’s clinical trials to identify patients with low level of hENT1 expression in the tumor. All costs under this agreement will be borne by Clovis Oncology.

Clavis Pharma also retains the rights to use the hENT1 antibody to develop companion diagnostics on other assay platforms for the evaluation of hENT1 status in regard to clinical and commercial use with its other product candidates, such as elacytarabine and CP-4200.

https://www.bionity.com/en/news/117148/clavis-pharma-licenses-rights-to-hent1-antibody-to-ventana-medical-systems-inc.html